CALT Calliditas Therapeutics AB

22.22
-1.39  -6%
Previous Close 23.61
Open 23.5
52 Week Low 19
52 Week High 24.97
Market Cap $532,595,713
Shares 23,969,204
Float 23,969,204
Enterprise Value $501,358,539
Volume 18,030
Av. Daily Volume 0
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
Nefecon (NefIgArd)
IgA nephropathy
Phase 3
Phase 3
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Latest News

  1. STOCKHOLM, July 2, 2020 /PRNewswire/ -- Citigroup Global Markets Inc. ("Citigroup"), in its capacity as Joint Global Coordinator, notifies that the stabilization period relating to Calliditas Therapeutics AB (publ)'s ("Calliditas" or the "Company") American Depositary Shares ("ADSs"), traded on The Nasdaq Global Select Market has ended and no further stabilization transactions will be effected. The over-allotment option is partially exercised by Citigroup and Jefferies LLC on behalf of the underwriters, which means that 706,676 new common shares, represented by 353,338 ADSs, will be issued by the Company.

    As announced by the Company in connection with the initial public offering on The Nasdaq Global Select Market, by way of an issuance of new…

    STOCKHOLM, July 2, 2020 /PRNewswire/ -- Citigroup Global Markets Inc. ("Citigroup"), in its capacity as Joint Global Coordinator, notifies that the stabilization period relating to Calliditas Therapeutics AB (publ)'s ("Calliditas" or the "Company") American Depositary Shares ("ADSs"), traded on The Nasdaq Global Select Market has ended and no further stabilization transactions will be effected. The over-allotment option is partially exercised by Citigroup and Jefferies LLC on behalf of the underwriters, which means that 706,676 new common shares, represented by 353,338 ADSs, will be issued by the Company.

    As announced by the Company in connection with the initial public offering on The Nasdaq Global Select Market, by way of an issuance of new common shares in the form of ADSs, each representing two (2) underlying new common shares of Calliditas, (the "U.S. Offering"), and a concurrent private placement of common shares to certain qualified investors in Europe and certain other jurisdictions outside of the United States (together with the U.S. Offering, the "Global Offering"), Citigroup may, acting as Joint Global Coordinator and stabilization manager, carry out transactions aimed at supporting the market price of the ADSs at levels above those which might otherwise prevail in the market.

    Stabilization transactions have been possible to undertake on The Nasdaq Global Select Market, in the over-the-counter market or otherwise, at any time during the period starting on the day of pricing of the ADSs on The Nasdaq Global Select Market, June 4, 2020, and ending no later than 30 calendar days thereafter. Citigroup has, however, not been obliged to undertake any stabilization and there was no assurance that stabilization would be undertaken. Undertaken stabilization has been possible to discontinue at any time without prior notice. In no event has transactions been effected at a price higher than the price in the U.S. Offering, i.e. USD 19.50. No stabilization measures have taken or will take place on Nasdaq Stockholm.

    The board of directors of the Company has granted Citigroup, Jefferies LLC and Stifel, Nicolaus & Company, Inc. (together the "Book Running Managers") an over-allotment option, which may be utilized in whole or in part for 30 days from the day of pricing of the ADSs on The Nasdaq Global Select Market, to issue up to 692,306 ADSs, representing 1,384,612 underlying common shares, corresponding to up to 15 percent of the total number of common shares in the Global Offering, at a price corresponding to the price in the U.S. Offering, to cover any over-allotment in connection with the Global Offering (the "Over-allotment option"). The Book Running Managers now notify that the Over-allotment option with respect to 353,338 ADSs, representing 706,676 common shares has been exercised. The Company will thereby be provided with additional gross proceeds of approximately USD 6,890,000, which means that the Company has been provided with in total approximately USD 96,890,000, corresponding to approximately SEK 902,666,000, in gross proceeds as a result of the Global Offering and the Over-allotment option. Immediately following registration of the new common shares issued pursuant to the Over-allotment option, the number of common shares and votes in the Company will amount to 49,161,584 and the number of issued ADSs will amount to 4,506,723.

    Citigroup has, in its capacity as stabilization manager, on June 12 and June 24, 2020 notified in accordance with article 5(4) in the Market Abuse Regulation 596/2014 that stabilization measures have been undertaken, in accordance with Reg M, Rule 104 of the U.S. Securities Act of 1933, as amended, on The Nasdaq Global Select Market as specified below. No stabilization measures have been undertaken since June 24, 2020. The contact person at Citigroup is Dean Poniros (tel: +1 212 723 6137, e-mail: ).

                                       

                                       

    Stabilization information:

                                       

    Issuer:

                                       

    Calliditas Therapeutics AB (publ)

                                                   

                                       

    Securities:

                                       

    American Depositary Shares (ISIN: US13124Q1067)

                                                   

                                       

    Offering size:

                                       

    692,306 ADSs, representing 1,384,612 underlying common shares

                                                   

                                       

    Offer price:

                                       

    USD 19.50

                                                   

                                       

    Ticker:

                                       

    CALT

                                                   

                                       

    Stabilization manager:

                                       

    Citigroup Global Markets Inc.

                                       

    The stabilization period regarding the Global Offering has now ended and no further stabilization transactions will be effected. Specified below is a summary of the stabilization transactions which have been effected during the stabilization period in accordance with the press releases of June 12 and June 24, 2020, respectively. All transactions during the stabilization period have been effected on The Nasdaq Global Select Market and no stabilization transactions have been effected on other dates than those specified below.

                                       

                                       

    Stabilization transactions:

                                       

    Date

                                       

    Quantity,  ADS

                                       

    Price (highest)

                                       

    Price (lowest)

                                       

    Price (volume weighted average)

                                       

    Currency

                                       

    Trading venue

                                                   

                                       

    2020-06-05

     

    296,174

     

    19.50

     

    19.50

     

    19.50

                                       

    USD

                                       

    The Nasdaq Global Select Market

                                                   

                                       

    2020-06-11

     

    30,221

     

    19.50

     

    19.40

     

    19.4827

                                       

    USD

                                       

    The Nasdaq Global Select Market

                                                   

                                       

    2020-06-12

     

    2,319

     

    19.40

     

    19.40

     

    19.40

                                       

    USD

                                       

    The Nasdaq Global Select Market

                                                   

                                       

    2020-06-15

     

    75

     

    19.25

     

    19.25

     

    19.25

                                       

    USD

                                       

    The Nasdaq Global Select Market

                                                   

                                       

    2020-06-16

     

    600

     

    19.25

     

    19.25

     

    19.25

                                       

    USD

                                       

    The Nasdaq Global Select Market

                                                   

                                       

    2020-06-18

     

    4,666

     

    19.15

     

    19.15

     

    19.15

                                       

    USD

                                       

    The Nasdaq Global Select Market

                                                   

                                       

    2020-06-19

     

    4,913

     

    19.00

     

    19.00

     

    19.00

                                       

    USD

                                       

    The Nasdaq Global Select Market

                                       

    This information is information that Calliditas is obliged to make public pursuant to the EU Market Abuse Regulation 596/2014. The information was submitted for publication, through the agency of the contact person set out above, at 8.45 am CEST on July 2, 2020.

    About Calliditas

    Calliditas Therapeutics AB is a specialty pharmaceutical company based in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which Calliditas can partially or completely participate in the commercialization efforts. Calliditas is focused on the development and commercialization of the product candidate Nefecon, a unique two step formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the United States. Calliditas is listed on Nasdaq Stockholm (TICKER:CALTX) and The Nasdaq Global Select Market (NASDAQ:CALT).              

    Important information

    This announcement does not constitute an offer to sell nor a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    No announcements or information regarding the initial public offering may be disseminated to the public in jurisdictions where a prior registration or approval is required for such purpose. No steps have been taken, or will be taken, for the offering of Shares or ADSs in any jurisdiction where such steps would be required. The issue or sale of shares or ADSs, and the subscription for or purchase of shares or ADSs are subject to special legal or statutory restrictions in certain jurisdictions. Calliditas is not liable if these restrictions are not complied with by any other person.

    This announcement is not a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. Calliditas has not authorized any offer to the public of shares or rights in any member state of the EEA and no prospectus has been or will be prepared in connection therewith. In any EEA member state, this communication is only addressed to and is only directed at qualified investors in that member state within the meaning of the Prospectus Regulation.

    In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, "qualified investors" who are (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons"). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this document and should not act or rely on it.

    For further information, please contact:

    Renée Aguiar-Lucander, CEO at Calliditas

    E-mail:

    Telephone: +46-722-52-10-06

    Mikael Widell, Head of Communications at Calliditas

    E-mail:

    Telephone: +46-703-11-99 60

    www.calliditas.se/en/-

    This information was brought to you by Cision http://news.cision.com

    https://news.cision.com/calliditas-therapeutics/r/exercise-of-over-allotment-option-and-end-of-the-stabilization-period,c3147126

    The following files are available for download:

     

    Cision View original content:http://www.prnewswire.com/news-releases/exercise-of-over-allotment-option-and-end-of-the-stabilization-period-301087498.html

    SOURCE Calliditas Therapeutics

    View Full Article Hide Full Article
  2. STOCKHOLM, June 30, 2020 /PRNewswire/ -- During June, Calliditas Therapeutics AB (publ) has issued 9,230,770 common shares as a result of the initial public offering on The Nasdaq Global Select Market in the United States and concurrent private placement of common shares to certain qualified investors in Europe and certain other jurisdictions outside of the United States. Thus, as of June 30, 2020, the number of shares and votes in the Company amounts to 47,938,408.

    For further information, please contact:

    Renée Aguiar-Lucander, CEO at Calliditas

    Tel.: +46-722-52-10-06, email:

    Mikael Widell, Head of Communications and IR

    Tel.: +46-703-11-99-60, email:

    The information in the press

    STOCKHOLM, June 30, 2020 /PRNewswire/ -- During June, Calliditas Therapeutics AB (publ) has issued 9,230,770 common shares as a result of the initial public offering on The Nasdaq Global Select Market in the United States and concurrent private placement of common shares to certain qualified investors in Europe and certain other jurisdictions outside of the United States. Thus, as of June 30, 2020, the number of shares and votes in the Company amounts to 47,938,408.

    For further information, please contact:

    Renée Aguiar-Lucander, CEO at Calliditas

    Tel.: +46-722-52-10-06, email:

    Mikael Widell, Head of Communications and IR

    Tel.: +46-703-11-99-60, email:

    The information in the press release is such that Calliditas Therapeutics AB (publ) is required to disclose pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, at 5.30 pm CEST on June 30, 2020.

    About Calliditas

    Calliditas Therapeutics is a specialty pharmaceutical company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Calliditas' lead product candidate, Nefecon, is a proprietary, novel oral formulation of budesonide, an established, highly potent local immunosuppressant, for the treatment of the autoimmune renal disease IgA nephropathy, or IgAN, for which there is a high unmet medical need and there are no approved treatments. Calliditas is running a global Phase 3 study within IgAN and, if approved, aims to commercialize Nefecon in the United States. Calliditas is listed on Nasdaq Stockholm (TICKER:CALTX) and the Nasdaq Global Select Market (NASDAQ:CALT). Visit www.calliditas.com for further information.

    This information was brought to you by Cision http://news.cision.com

    https://news.cision.com/calliditas-therapeutics/r/number-of-shares-and-votes-in-calliditas-therapeutics,c3144749

    The following files are available for download:

    Cision View original content:http://www.prnewswire.com/news-releases/number-of-shares-and-votes-in-calliditas-therapeutics-301086055.html

    SOURCE Calliditas Therapeutics

    View Full Article Hide Full Article
  3. STOCKHOLM, June 25, 2020 /PRNewswire/ -- The following resolutions were passed at Calliditas Therapeutics AB (publ) ("Calliditas") annual general meeting held today, on June 25, 2020, in Stockholm.

    Adoption of income statement and balance sheet for the financial year 2019 and discharge from liability

    The annual general meeting resolved to adopt the income statement and the consolidated income statement for the financial year 2019 as well as the balance sheet and consolidated balance sheet as of 31 December 2019. The members of the board of directors and the managing director were discharged from liability for the financial year 2019.

    Allocation of profit or loss

    The annual general meeting resolved, in accordance with the board of directors…

    STOCKHOLM, June 25, 2020 /PRNewswire/ -- The following resolutions were passed at Calliditas Therapeutics AB (publ) ("Calliditas") annual general meeting held today, on June 25, 2020, in Stockholm.

    Adoption of income statement and balance sheet for the financial year 2019 and discharge from liability

    The annual general meeting resolved to adopt the income statement and the consolidated income statement for the financial year 2019 as well as the balance sheet and consolidated balance sheet as of 31 December 2019. The members of the board of directors and the managing director were discharged from liability for the financial year 2019.

    Allocation of profit or loss

    The annual general meeting resolved, in accordance with the board of directors' proposal, that no dividend shall be paid for 2019 and that the results of the Company shall be carried forward.

    Election of board members, auditors, fees to the board of directors and auditors

    The annual general meeting resolved, in accordance with the nomination committee's proposal, that the number of members of the board of directors shall be five without deputies and that the number of auditors shall be one without deputies.

    In accordance with the nomination committee's proposal, Elmar Schnee, Hilde Furberg, Lennart Hansson and Diane Parks were re-elected as members of the board of directors, and Molly Henderson was elected as new member of the board of directors, for the period until the end of the next annual general meeting. Elmar Schnee was re-elected as the chairman of the board of directors. The audit firm Ernst & Young AB was elected auditor of the Company for the period until the end of the next annual general meeting, and it was noted that the authorized public accountant Fredrik Norrman will continue as auditor in charge.

    The annual general meeting further resolved, in accordance with the nomination committee's proposal and for the time period until the end of the next annual general meeting, that the directors' fees shall be paid in the amount of SEK 850,000 to the chairman of the board of directors and in the amount of SEK 250,000 to each of the other members, with SEK 150,000 to the chairman of the audit committee and with 75,000 SEK to the other members of the audit committee as well as with SEK 50,000 to the chairman of the remuneration committee and SEK 25,000 to the other members of the remuneration committee. In addition to the above remuneration, it was determined that board members residing in the United States shall receive an additional amount of SEK 140,000 and that board members residing in Europe, but outside the Nordics, shall receive an additional amount of SEK 50,000. The annual general meeting further resolved, in accordance with the nomination committee's proposal, that the remuneration to the auditor shall be paid in accordance with approved statement of costs.

    Nomination committee for the next annual general meeting

    The annual general meeting resolved, in accordance with the nomination committee's proposal, on principles for appointing the nomination committee. In short, the nomination committee should be composed of the chairman of the board of directors together with one representative of each of the three largest shareholders, based on ownership in the Company as of the expiry of the third quarter of the financial year.

    Guidelines on remuneration to group management and board members

    The annual general meeting resolved, in accordance with the proposal from the board of directors, on guidelines for remuneration to group management and board members. In short, the guidelines state that remuneration within Calliditas shall be based on principles of performance, competitiveness and fairness. The remuneration to group management and board members may consist of fixed remuneration, variable remuneration, share and share price-related incentive programs, pension and other benefits.

    Long-term performance-based incentive program for certain members of the board of directors

    The annual general meeting resolved, in accordance with the nomination committee's proposal, to adopt a new long-term performance-based incentive program for certain members of the board of directors, including a resolution to issue not more than 40,000 warrants to ensure delivery of shares to participants under the program. The incentive program entails that main owner independent members of the board of directors will be granted share awards, free of charge, that can entitle to shares in Calliditas, subject to the fulfilment of certain performance conditions.

    Authorization to issue new shares

    The annual general meeting resolved, in accordance with the board of directors' proposal, to authorize the board of directors, at one or several occasions and for the period up until the next annual general meeting, to increase the Company's share capital by issuing new shares. Such share issue resolution may be carried out with or without deviation from the shareholders' preferential rights and with or without provisions for contribution in kind, set-off or other conditions. The authorization may only be utilised to the extent that it corresponds to a dilution of not more than 20 per cent of the total number of shares outstanding at the time of the general meeting's resolution on the proposed authorization.

    Amendment to the articles of association

    The annual general meeting resolved, in accordance with the board of directors' proposal, to amend the articles of association by introduction of a new section regarding forum for resolving any complaint in the United States, should such be filed.

    For further information, please contact:

    Mikael Widell, Head of Communications

    Email:

    Telephone: +46-703-11 99 60

    The information was submitted for publication, through the agency of the contact person set out above, at 6.30 pm CEST on June 25, 2020.

    About Calliditas

    Calliditas Therapeutics is a specialty pharmaceutical company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Calliditas' lead product candidate, Nefecon, is a proprietary, novel oral formulation of budesonide, an established, highly potent local immunosuppressant, for the treatment of the autoimmune renal disease IgA nephropathy, or IgAN, for which there is a high unmet medical need and there are no approved treatments. Calliditas is running a global Phase 3 study within IgAN and, if approved, aims to commercialize Nefecon in the United States. Calliditas is listed on Nasdaq Stockholm (TICKER:CALTX) and the Nasdaq Global Select Market (NASDAQ:CALT). Visit www.calliditas.com for further information.

    This information was brought to you by Cision http://news.cision.com

    https://news.cision.com/calliditas-therapeutics/r/bulletin-from-the-annual-general-meeting-of-calliditas-therapeutics-ab--publ-,c3142257

    The following files are available for download:

    Cision View original content:http://www.prnewswire.com/news-releases/bulletin-from-the-annual-general-meeting-of-calliditas-therapeutics-ab-publ-301083874.html

    SOURCE Calliditas Therapeutics

    View Full Article Hide Full Article
  4. STOCKHOLM, June 25, 2020 /PRNewswire/ -- Citigroup Global Markets Inc. ("Citigroup"), in its capacity as Joint Global Coordinator, notifies that stabilization measures have been undertaken in Calliditas Therapeutics AB's ("Calliditas" or the "Company") American Depositary Shares ("ADSs"), traded on The Nasdaq Global Select Market.

    As announced by the Company in connection with the initial public offering on The Nasdaq Global Select Market, by way of a capital increase of new common shares in the form of ADSs, each representing two (2) underlying new common shares of Calliditas, (the "U.S. Offering"), and a concurrent private placement of common shares to certain qualified investors in Europe and certain other jurisdictions outside of the United

    STOCKHOLM, June 25, 2020 /PRNewswire/ -- Citigroup Global Markets Inc. ("Citigroup"), in its capacity as Joint Global Coordinator, notifies that stabilization measures have been undertaken in Calliditas Therapeutics AB's ("Calliditas" or the "Company") American Depositary Shares ("ADSs"), traded on The Nasdaq Global Select Market.

    As announced by the Company in connection with the initial public offering on The Nasdaq Global Select Market, by way of a capital increase of new common shares in the form of ADSs, each representing two (2) underlying new common shares of Calliditas, (the "U.S. Offering"), and a concurrent private placement of common shares to certain qualified investors in Europe and certain other jurisdictions outside of the United States (together with the U.S. Offering, the "Global Offering"), Citigroup may, acting as Joint Global Coordinator and stabilization manager, carry out transactions aimed at supporting the market price of the ADSs at levels above those which might otherwise prevail in the market.

    Stabilization transactions may be undertaken on The Nasdaq Global Select Market, in the over-thecounter market or otherwise, at any time during the period starting on the day of pricing of the ADSs on The Nasdaq Global Select Market, 4 June 2020, and ending no later than 30 calendar days thereafter. Citigroup is, however, not required to undertake any stabilization and there is no assurance that stabilization will be undertaken. Stabilization, if undertaken, may be discontinued at any time without prior notice. In no event will transactions be effected at a price higher than the price in the U.S. Offering, i.e. USD 19.50. No stabilization measures have taken or will take place on Nasdaq Stockholm.

    The board of directors of the Company have granted the Joint Global Coordinators an over-allotment option which may be utilized in whole or in part for 30 days from the date of pricing of the Company's ADSs, to sell up to 692,306 ADS corresponding to up to 15 percent of the total number of common shares in the Global Offering, at a price corresponding to the price in the U.S. Offering, i.e. USD 19.50 per ADS, to cover any over-allotment in connection with the Global Offering.

    Citigroup has, in its capacity as stabilization manager, notified in accordance with article 5(4) in the Market Abuse Regulation 596/2014 that stabilization measures have been undertaken, in accordance with Reg M, Rule 104 of the U.S. Securities Act of 1933, as amended, on The Nasdaq Global Select Market as specified below. Undertaken stabilization measures were also announced on 12 June 2020. The contact person at Citigroup is Dean Poniros (tel: +1 212 723 6137, e-mail: ).

    Stabilization information:

    Issuer:

    Calliditas Therapeutics AB (publ)

    Securities:

    American Depositary Shares (ISIN: US13124Q1067)

    Offering size:

    692,306 ADSs, representing 1,384,612 underlying common shares

    Offer price:

    USD 19.50

    Ticker:

    CALT

    Stabilization manager:

    Citigroup Global Markets Inc.

    Stabilization transactions:

    Date

    Quantity,  ADS

    Price (highest)

    Price (lowest)

    Price (volume weighted average)

    Currency

    Trading venue

    2020-06-15

    75

    19.25

    19.25

    19.25

    USD

    The Nasdaq Global Select Market

    2020-06-16

    600

    19.25

    19.25

    19.25

    USD

    The Nasdaq Global Select Market

    2020-06-18

    4,666

    19.15

    19.15

    19.15

    USD

    The Nasdaq Global Select Market

    2020-06-19

    4,913

    19.00

    19.00

    19.00

    USD

    The Nasdaq Global Select Market

     

    www.calliditas.se/en/

    This information is information that Calliditas is obliged to make public pursuant to the EU Market Abuse Regulation 596/2014. The information was submitted for publication, through the agency of the contact person set out below, at 10:45 pm CEST on 24 June 2020.

    About Calliditas

    Calliditas Therapeutics AB is a specialty pharmaceutical company based in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which Calliditas can partially or completely participate in the commercialization efforts. Calliditas is focused on the development and commercialization of the product candidate Nefecon, a unique two step formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the United States. Calliditas is listed on Nasdaq Stockholm (TICKER:CALTX) and The Nasdaq Global Select Market (NASDAQ:CALT).

    For further information, please contact:

    Renée Aguiar-Lucander, CEO at Calliditas

    E-mail:

    Telephone: +46 722 52 10 06

    Mikael Widell, Head of Communications at Calliditas

    E-mail:

    Telephone: +46 703 11 99 60

    This information was brought to you by Cision http://news.cision.com

    https://news.cision.com/calliditas-therapeutics/r/citigroup-notifies-that-stabilization-measures-have-been-undertaken-in-calliditas-therapeutics--adss,c3141344

    The following files are available for download:

    Cision View original content:http://www.prnewswire.com/news-releases/citigroup-notifies-that-stabilization-measures-have-been-undertaken-in-calliditas-therapeutics-adss-traded-on-the-nasdaq-global-select-market-301083385.html

    SOURCE Calliditas Therapeutics

    View Full Article Hide Full Article
  5. STOCKHOLM, June 22, 2020 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") today announced that its CEO Renée Aguiar-Lucander will exercise warrants granted pursuant to Calliditas' Warrant Program 2017/2020, which corresponds to an investment totaling SEK 15.7 million. Following the exercise, Ms. Aguiar-Lucander's total shareholding in Calliditas corresponds to 412,000 shares.

    The information was sent for publication, through the agency of the contact persons set out above, on June 22, 2020 at 8:00 a.m. CET.

    About Calliditas

    Calliditas Therapeutics is a specialty pharmaceutical company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus…

    STOCKHOLM, June 22, 2020 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") today announced that its CEO Renée Aguiar-Lucander will exercise warrants granted pursuant to Calliditas' Warrant Program 2017/2020, which corresponds to an investment totaling SEK 15.7 million. Following the exercise, Ms. Aguiar-Lucander's total shareholding in Calliditas corresponds to 412,000 shares.

    The information was sent for publication, through the agency of the contact persons set out above, on June 22, 2020 at 8:00 a.m. CET.

    About Calliditas

    Calliditas Therapeutics is a specialty pharmaceutical company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Calliditas' lead product candidate, Nefecon, is a proprietary, novel oral formulation of budesonide, an established, highly potent local immunosuppressant, for the treatment of the autoimmune renal disease IgA nephropathy, or IgAN, for which there is a high unmet medical need and there are no approved treatments. Calliditas is running a global Phase 3 study within IgAN and, if approved, aims to commercialize Nefecon in the United States. Calliditas is listed on Nasdaq Stockholm (TICKER:CALTX) and the Nasdaq Global Select Market (NASDAQ:CALT). Visit www.calliditas.com for further information.

    For further information, please contact:

    Renée Aguiar-Lucander

    CEO, Calliditas

    Email:

    Telephone: +46-722-52-10-06

    Mikael Widell

    Head of Communications

    Email:

    Telephone: +46-703-11-99-60

    This information was brought to you by Cision http://news.cision.com

    https://news.cision.com/calliditas-therapeutics/r/ceo-renee-aguiar-lucander-exercises-warrants-and-invests-sek-15-7m--appr--usd-1-7m--in-calliditas,c3138657

    The following files are available for download:

    Cision View original content:http://www.prnewswire.com/news-releases/ceo-renee-aguiar-lucander-exercises-warrants-and-invests-sek-15-7m-appr-usd-1-7m-in-calliditas-301080842.html

    SOURCE Calliditas Therapeutics

    View Full Article Hide Full Article
View All Calliditas Therapeutics AB News